ActualitésAssisté par IA

Celularity’s Natalin and Acelagraft™ Receive FDA TRG Recommendations

Celularity’s placental biomaterials, Natalin and Acelagraft™, gain FDA TRG recommendation for wound care use.

Par Mrudula Kulkarni

Rédacteur en chef - Pharma Now

26 févr. 2025Updated Jun 26, 2025 · 2 min de lecture

Partager Ajouter comme source préférée

Celularity’s Natalin and Acelagraft™ Receive FDA TRG Recommendations — https://www.google.com/imgres?imgurl=https%3A%2F%2Fhealthful-plus.com%2Fwp-content%2Fuploads%2F2025%2F01%2Fs2.jpeg&tbnid=qRTh1F6gZpFx8M&vet=10CBYQxiAoBWoXChMIsJSKp9bgiwMVAAAAAB0AAAAAEAc..i&imgrefurl=https%3A%2F%2Fhealthful-plus.com%2Fcomprehensive-guide-to-the-fda-approval-process-for-new-drugs%2F&docid=-ytfw-l-tsb6UM&w=1200&h=628&itg=1&q=fda&ved=0CBYQxiAoBWoXChMIsJSKp9bgiwMVAAAAAB0AAAAAEAc

Journalisme assisté par IA

Reviewed by Mrudula Kulkarni, Rédacteur en chef - Pharma Now

Celularity Inc. has received key recommendation letters from the FDA’s Tissue Reference Group (TRG) confirming that its regenerative medicine products, Natalin and Acelagraft™, meet the criteria for regulation solely under section 361 of the Public Health Service Act. This designation allows the company to market these human cell and tissue-based products (HCT/Ps) for use in treating acute and chronic wounds, reinforcing Celularity’s position in the rapidly growing wound care market.

Dr. Robert Hariri, Celularity’s Chairman and CEO, expressed enthusiasm for the regulatory milestone, calling it a testament to the company’s commitment to innovation in placental-derived biomaterials. With the global biological skin substitutes market expected to reach $810.5 million by 2034, Celularity is well-positioned to capitalize on the expanding demand, particularly in North America, which currently holds the largest market share.

SujetsActualités

Written by

Mrudula Kulkarni

Rédacteur en chef - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.